Immune tolerance induced using plasma exchange and rituximab in an infantile pompe disease patient

Journal of Child Neurology

Volumn 29, Issue 6, 2014, Pages 850-854

  Deodato, Federica ^a   Ginocchio, Virginia Maria ^a   Onofri, Alfredo ^a   Grutter, Giorgia ^a   Germani, Alessandro ^a   Dionisi Vici, Carlo ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Anti recombinant human acid glucosidase antibodies; Immune modulation; Lysosomal; Pompe; Rituximab

Indexed keywords

ALPHA GLUCOSIDASE ANTIBODY; ENZYME ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RITUXIMAB; UNCLASSIFIED DRUG; ALPHA-GLUCURONIDASE; ANTIBODY; GLYCOSIDASE; IMMUNOLOGIC FACTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY TITER; APHERESIS DEVICE; ARTICLE; CASE REPORT; DESENSITIZATION; DISEASE SEVERITY; ENZYME REPLACEMENT; GENOTYPE; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFANT; JOINT CONTRACTURE; MALE; MUSCLE HYPOTONIA; PLASMAPHERESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; BLOOD; CONSANGUINITY; DRUG EFFECTS; GLYCOGEN STORAGE DISEASE TYPE II; IMMUNOLOGY;

ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; CONSANGUINITY; GLYCOGEN STORAGE DISEASE TYPE II; GLYCOSIDE HYDROLASES; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; INFANT; PLASMA EXCHANGE;

EID: 84903518026     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073813485819     Document Type: Article

References (11)

1. van den Hout HMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112:332-340.
2. Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009;11: 210-219.
3. Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26-33.
4. Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011; 13:729-736.
5. Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating a-glucosidase replacement therapy for Pompe disease. Pediatrics. 2004;114:e532-e535. (Pubitemid 41529751
6. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med. 2009;360:194-195.
7. Messinger HY, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;12: 135-142.
8. Banugaria SG, Patel TT, Mackey J, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab. 2012;105:677-680.
9. Banugaria SG, Patel TT, Kishnani PS. Immune modulation in Pompe disease treated with enzyme replacement therapy. Expert Rev Clin Immunol. 2012;8:497-499.
10. Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2013;15:123-131.
11. Angelini C, Semplicini C. Enzyme replacement therapy for Pompe disease. Curr Neurol Neurosci Rep. 2012;12:70-75.